Skip to main content

CG Oncology, Inc.

For the period ended Mar 31, 2025. Filed May 13, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 13, 2025

CGON$74.74-1.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

March 31,December 31,
20252024
Assets · (unaudited)
Current assets:
Cash and cash equivalents$41,472$257,068
Marketable securities646,962484,930
Prepaid expenses and other current assets12,41311,431
Accounts receivable - other345781
Total current assets701,192754,210
Property and equipment, net264272
Note receivable, net25,176—
Operating lease right-of-use assets1,033221
Other assets51694
Total assets$728,181$754,797
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$6,731$6,517
Operating lease liabilities, current portion255186
Accrued expenses and other current liabilities15,65614,665
Total current liabilities22,64221,368
Operating lease liabilities, net of current portion78152
Total liabilities23,42321,420
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.0001 par value per share; 700,000,000 and 700,000,000 shares authorized as of March 31, 2025 and December 31, 2024, respectively; 76,221,289 and 76,154,783 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively88
Additional paid-in capital957,183951,350
Accumulated deficit(252,433)(217,981)
Total stockholders' equity704,758733,377
Total liabilities and stockholders' equity$728,181$754,797
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.